Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

OptimizeRx Corp Director's Dealing 2020

Mar 13, 2020

33090_dirs_2020-03-13_d2f6aaca-6d33-40c8-a8d9-d2cb2f22ef37.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2020-03-11

Reporting Person: BAKER DOUGLAS P (CHIEF FINANCIAL OFFICER)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-03-11 Stock Option $7.51 A 63558 Acquired 2025-03-11 Common Stock (63558) Direct

Footnotes

F1: The Stock Option will vest 25% at the end of each quarter starting on 3/31/2020.